Industry Insights

Human tissues in drug discovery

Species differences: better predicting drug activity. By Dr Emma Moss
In this article, Dr Emma Moss of Biopta considers whether species differences really matter during preclinical drug discovery. It is well known that the drug development process frequently uses in vitro and in vivo animal models to try and predict the safety and efficacy of drugs in humans, but is this a suitable approach and what can be done to address situations where species differences are identified? Download this article to learn more about comparative methods across species.
Read More »

Could fresh human tissues be the missing link for stratified medicine? By Dr David Bunton
Patient stratification in clinical trials is seen as the future, but in order to design smarter trials, how will companies predict which patient sub-populations respond to their drugs during early nonclinical development? This article discusses the need for early patient stratification and looks at possible models to characterise patient "responders" and "non-responders" based on the use of fresh diseased tissues from the target patient population.
Read More »

The benefits of performing studies in fresh human tissue: De-risking the drug discovery process. By Dr Laura Antos
When is it important to use fresh human tissues and why might it be important to consider how to consider the relative advantages of cell lines and native tissues? This article explores the advantages of native tissues compared with cell lines for extrapolating the properties of a compound in these systems relative to that in the native human setting.
Read More »

The power of fresh human tissue studies in your R&D programmes. By Dr Keith Bowers
The pharmaceutical industry has undergone a major shift in recent years, moving towards outsourced specialist providers who are often focussed on new translational models with the promise of improved clinical success rates. In this article Dr Keith Bowers discusses the interaction between pharma and outsourced contract research providers and gives his perspective as a scientist of 20 years standing in the pharmaceutical industry.
Read More »

Future of human tissue research. By Dr David Bunton
Fresh, functional human tissues have long been considered the closest possible model of human in vivo function and can be used to measure a wide range of pharmacological responses. Access here a link to Biopta's article in volume 12 of Cell and Tissue Banking, which discusses both of these factors and looks to the future of human tissue research.
Read More »

Species Differences in the Control of Gastric Motility
Are species differences important to our understanding of preclinical to clinical translation. ? This article explores the responses to a common drug, erythromycin, and its effects on gastric motility. Do the marked species differences between humans, rats, rabbits and guinea pigs have any implications for models of gastric prokinetic effects?
Read More »

Not Just a Gut Feeling - GI Foresight
Knowledge of how drugs affect the gastrointestinal (GI) tract is extremely important in the drug development process. Our latest Industry Insight article discusses the challenges associated with adverse GI side effects and demonstrates how Biopta’s functional tissue assays can help overcome these challenges.
Read More »

Assessing Gastrointestinal Toxicity Using Human Fresh Tissues
The prediction of gastrointestinal safety ranges from effects that are potentially life-threatening (such as gastric bleeding with NSAIDs) to those which may appear less severe (such as changes in GI motility) but can have a high impact on patient compliance.
Read More »

Live chat by BoldChat